Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LFWD Lifeward	$0.62 -0.6%	$0.72	$0.50 ▼ $4.00	$9.74M	0.09	1.28 million shs	125,473 shs
OSRH OSR	$0.74 -16.0%	$0.98	$0.45 ▼ $13.40	$15.97M	1.49	3.76 million shs	975,503 shs
POAI Predictive Oncology	$0.90 -1.3%	$0.83	$0.55 ▼ $3.06	$9.83M	1.18	1.88 million shs	60,766 shs
XAGE Longevity Health	$2.58 -5.5%	$3.03	$2.15 ▼ $38.10	$4.60M	0.51	997,777 shs	6,312 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LFWD Lifeward	-1.59%	+1.47%	-23.38%	-51.18%	-81.87%
OSRH OSR	-9.90%	+75.77%	-6.59%	-27.76%	+88,129,900.00%
POAI Predictive Oncology	+2.69%	+1.54%	+14.24%	+0.43%	+0.86%
XAGE Longevity Health	-1.09%	+8.33%	-30.18%	+272,999,900.00%	+272,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
LFWD Lifeward	2.8261 of 5 stars	3.5	4.0	0.0	0.0	2.2	0.0	1.3
OSRH OSR	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
POAI Predictive Oncology	0.4969 of 5 stars	0.0	3.0	0.0	0.0	2.6	0.0	0.6
XAGE Longevity Health	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
LFWD Lifeward	3.00	Buy	$9.00	1,351.38% Upside
OSRH OSR	0.00	N/A	N/A	N/A
POAI Predictive Oncology	2.00	Hold	N/A	N/A
XAGE Longevity Health	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
LFWD Lifeward	$24.43M	0.40	N/A	N/A	$0.96 per share	0.65
OSRH OSR	N/A	N/A	N/A	N/A	$6.45 per share	N/A
POAI Predictive Oncology	$1.66M	5.90	N/A	N/A	($0.15) per share	-6.01
XAGE Longevity Health	$1.05M	4.37	N/A	N/A	($2.10) per share	-1.23

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
LFWD Lifeward	-$28.94M	-$3.12	N/A	N/A	N/A	-121.80%	-137.91%	-90.28%	11/11/2025 (Estimated)
OSRH OSR	-$2.41M	N/A	0.00	∞	N/A	N/A	-12.19%	-8.18%	N/A
POAI Predictive Oncology	-$12.66M	-$3.05	N/A	N/A	N/A	-587.31%	-722.01%	-167.23%	11/11/2025 (Estimated)
XAGE Longevity Health	-$10.37M	N/A	0.00	∞	N/A	-682.67%	N/A	-261.90%	N/A

Latest XAGE, OSRH, POAI, and LFWD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	LFWD Lifeward	-$0.25	-$0.58	-$0.33	-$0.58	$6.62 million	$5.72 million
8/14/2025	Q2 2025	OSRH OSR	N/A	$0.02	N/A	$0.02	N/A	$1.14 million
8/14/2025	Q2 2025	XAGE Longevity Health	N/A	-$1.56	N/A	-$1.56	N/A	$0.50 million
8/13/2025	Q2 2025	POAI Predictive Oncology	-$0.09	-$0.22	-$0.13	-$0.23	$1.50 million	$0.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
LFWD Lifeward	N/A	N/A	N/A	N/A	N/A
OSRH OSR	N/A	N/A	N/A	N/A	N/A
POAI Predictive Oncology	N/A	N/A	N/A	N/A	N/A
XAGE Longevity Health	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
LFWD Lifeward	N/A	2.00	1.26
OSRH OSR	N/A	0.18	0.17
POAI Predictive Oncology	N/A	0.32	0.31
XAGE Longevity Health	N/A	0.47	0.30

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
LFWD Lifeward	26.76%
OSRH OSR	55.30%
POAI Predictive Oncology	9.04%
XAGE Longevity Health	24.22%

Insider Ownership

Company	Insider Ownership
LFWD Lifeward	2.70%
OSRH OSR	33.67%
POAI Predictive Oncology	3.44%
XAGE Longevity Health	29.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
LFWD Lifeward	60	15.71 million	15.28 million	Optionable
OSRH OSR	N/A	21.58 million	14.32 million	N/A
POAI Predictive Oncology	30	10.89 million	10.52 million	Not Optionable
XAGE Longevity Health	14	1.78 million	1.27 million	N/A

XAGE, OSRH, POAI, and LFWD Headlines

Recent News About These Companies

Longevity Health (NASDAQ:XAGE) versus TransEnterix (OTCMKTS:TRXDW) Financial Contrast

August 19, 2025 | americanbankingnews.com

Why Longevity Health Stock Is Skyrocketing Today

July 15, 2025 | benzinga.com

Why Longevity Health Stock Is Skyrocketing Today

July 15, 2025 | benzinga.com

Why did XAGE Stock Surge in Today’s Premarket Trading?

July 15, 2025 | tokenist.comT

Longevity Health Holdings, Inc.: Longevity Health Holdings Announces Merger with THPlasma and Termination of 20/20 BioLabs Transaction

July 15, 2025 | finanznachrichten.de

Longevity Health Holdings to Merge With True Health

July 15, 2025 | marketwatch.com

Longevity Health stock soars after merger with THPlasma in all-stock deal

July 15, 2025 | investing.com

Longevity Health Holdings Announces Merger with THPlasma and Termination of 20/20 BioLabs Transaction

July 14, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

XAGE, OSRH, POAI, and LFWD Company Descriptions

Lifeward NASDAQ:LFWD

$0.62 0.00 (-0.61%)

Closing price 04:00 PM Eastern

Extended Trading

$0.62 0.00 (-0.18%)

As of 05:18 PM Eastern

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke. The company markets and sells its products directly to institutions and individuals, as well as through third-party distributors. The company was formerly known as Argo Medical Technologies Ltd. ReWalk Robotics Ltd. was incorporated in 2001 and is headquartered in Yokneam Illit, Israel.

OSR NASDAQ:OSRH

$0.74 -0.14 (-16.01%)

As of 04:00 PM Eastern

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D "platform technologies" versus "assets only" companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials. We focus on value creation through investments and collaborations with US and EU biotech companies, with the strategic goal of expansion into South Korea (specifically) and Asia (generally). OSR Holdings is headquartered in Paju, South Korea.

Predictive Oncology NASDAQ:POAI

$0.90 -0.01 (-1.30%)

Closing price 03:59 PM Eastern

Extended Trading

$0.91 +0.01 (+1.33%)

As of 04:48 PM Eastern

Predictive Oncology Inc. operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples. It operates through four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment provides services that include the application of AI, collaboration projects, and clinical testing. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using a self-contained automated system that conducts self-interaction chromatography screens using additives and excipients included in protein formulations resulting in soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is headquartered in Eagan, Minnesota.

Longevity Health NASDAQ:XAGE

$2.58 -0.15 (-5.49%)

As of 04:00 PM Eastern

Carmell Therapeutics Corporation focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing. The company was founded in 2008 and is based in Pittsburgh, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time